These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24510172)

  • 1. [Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].
    Meyer CH; Krohne TU
    Ophthalmologe; 2014 Feb; 111(2):104-6. PubMed ID: 24510172
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetics of the anterior eye].
    Bell K; Pfeiffer N; Grus FH
    Ophthalmologe; 2014 Feb; 111(2):107-12. PubMed ID: 24337342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of intravitreally administered VEGF inhibitors].
    Krohne TU; Holz FG; Meyer CH
    Ophthalmologe; 2014 Feb; 111(2):113-20. PubMed ID: 24346958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of systemic, regional and topical drugs for therapy of intraocular inflammation].
    Becker MD; Lortz S; Flückiger B; Luginbuehl V
    Ophthalmologe; 2014 Feb; 111(2):121-7. PubMed ID: 24337343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based ocular pharmacokinetic modeling using computational methods.
    Missel PJ; Sarangapani R
    Drug Discov Today; 2019 Aug; 24(8):1551-1563. PubMed ID: 31319151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmic drug dosage forms: characterisation and research methods.
    Baranowski P; Karolewicz B; Gajda M; Pluta J
    ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in ocular drug delivery.
    Chen H
    J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic adverse effects of topical ocular treatments.
    Labetoulle M; Frau E; Le Jeunne C
    Presse Med; 2005 Apr; 34(8):589-95. PubMed ID: 15962500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular delivery systems for topical application of anti-infective agents.
    Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R
    Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjuctival and eye drop administration in rabbits.
    Gough G; Szapacs M; Shah T; Clements P; Struble C; Wilson R
    Exp Eye Res; 2018 Feb; 167():14-17. PubMed ID: 29074387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive insight on ocular pharmacokinetics.
    Agrahari V; Mandal A; Agrahari V; Trinh HM; Joseph M; Ray A; Hadji H; Mitra R; Pal D; Mitra AK
    Drug Deliv Transl Res; 2016 Dec; 6(6):735-754. PubMed ID: 27798766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
    Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 15. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing systemic absorption of topically administered ophthalmic drugs.
    Urtti A; Salminen L
    Surv Ophthalmol; 1993; 37(6):435-56. PubMed ID: 8100087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.
    Le Merdy M; Fan J; Bolger MB; Lukacova V; Spires J; Tsakalozou E; Patel V; Xu L; Stewart S; Chockalingam A; Narayanasamy S; Rouse R; Matta M; Babiskin A; Kozak D; Choi S; Zhang L; Lionberger R; Zhao L
    AAPS J; 2019 May; 21(4):65. PubMed ID: 31111305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirements concerning antiseptics for periorbital, orbital and intraorbital application. Pharmacokinetics of ophthalmic drugs.
    Tawfik-Schlieper H
    Dev Ophthalmol; 2002; 33():66-84. PubMed ID: 12236129
    [No Abstract]   [Full Text] [Related]  

  • 19. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties.
    Subrizi A; Del Amo EM; Korzhikov-Vlakh V; Tennikova T; Ruponen M; Urtti A
    Drug Discov Today; 2019 Aug; 24(8):1446-1457. PubMed ID: 30738982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?
    Argikar UA; Dumouchel JL; Kramlinger VM; Cirello AL; Gunduz M; Dunne CE; Sohal B
    J Pharm Sci; 2017 Sep; 106(9):2276-2281. PubMed ID: 28322939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.